Tango Therapeutics (TNGX) EBT Growth (3y) (2023 - 2026)

Tango Therapeutics (TNGX) EBT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.22%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 12.16%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 86.16%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 41.79%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 95.61%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 38.36%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 64.03%
10 Tango Therapeutics 4.32 Bn 3.30 Bn - -38.91%

Historic Data

Download Data
DateValue
Jun 30, 2026 -38.91%
Mar 31, 2026 -17.57%
Dec 31, 2025 -10.18%
Sep 30, 2025 36.56%
Jun 30, 2025 -16.02%
Mar 31, 2025 -16.48%
Dec 31, 2024 -19.82%
Sep 30, 2024 -14.24%
Jun 30, 2024 -78.07%
Mar 31, 2024 -46.56%
Dec 31, 2023 -541.81%
Sep 30, 2023 6.03%
Jun 30, 2023 -3,423.42%